Detalhe da pesquisa
1.
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial.
Lancet
; 399(10343): 2294-2308, 2022 06 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-35717989
2.
Purification and kinetic characterization of human indoleamine 2,3-dioxygenases 1 and 2 (IDO1 and IDO2) and discovery of selective IDO1 inhibitors.
Biochim Biophys Acta
; 1814(12): 1947-54, 2011 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-21835273
3.
Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
Cancer Med
; 11(24): 4889-4899, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35619325
4.
Specific stimulation of MHC-transgenic mouse T-cell hybridomas with xenogeneic APC.
Hum Immunol
; 64(2): 238-44, 2003 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-12559626
5.
Expression of Trop2 cell surface glycoprotein in normal and tumor tissues: potential implications as a cancer therapeutic target.
J Histochem Cytochem
; 59(7): 701-10, 2011 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-21551320
6.
Antitumor vaccination with HER-2-derived recombinant antigens.
Int J Cancer
; 102(6): 660-4, 2002 Dec 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-12448011